# Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

> **NCT05002621** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 20 (actual)

## Conditions studied

- Eosinophilic Asthma

## Interventions

- **OTHER:** Observational

## Key facts

- **NCT ID:** NCT05002621
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-16
- **Primary completion:** 2023-02-13
- **Final completion:** 2025-12-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002621, "Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05002621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*